DOCSLIB.ORG

IPV Case Studies in Albania, Tunisia, and Nigeria

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IPV Case Studies in Albania, Tunisia, and Nigeria Case Studies of IPV Introduction: Albania, Nigeria, and Tunisia ACKNOWLEDGEMENTS This document is the result of the thinking, collaboration, and hard work of many people. We would like to thank the following group of individuals who played an instrumental role in the writing and review of this document: LEAD AUTHORS Lauren Platt, Katie Gorham, and Lois Privor-Dumm ALBANIA CASE STUDY Silvia Bino, Erida Nelaj, and Iria Preza NIGERIA CASE STUDY Chisom Obi, Shola Molemodile, Ifeyinwa Okoro, Tina Obande, and Chizoba Wonodi TUNISIA CASE STUDY Anne-Marie Giangiulio, Ramzi Ouhichi, Kamal Fahmy, and Essia Ben Farhat Hmida We would also like to thank the numerous people who graciously gave their time to be interviewed for this work and those that helped coordinate the case study, including: ALBANIA Albana Ahmeti, Gazmend Bejtja, Silvia Bino, Evgjeni Kaci, Eduard Kakarriqi, Georgina Kuli-Lito, Erida Nelaj, Iria Preza, and Klodjan Rjepaj NIGERIA Emmanuel Abanida, Toye Abolade, Mallam Bakoji Ahmed, Maryam Ali, Misbau Lawan Didi, Obi Ezebilo, Samuel Jiya, Gideon Kuje, Mustapha Mahmud, Pascal Mkanda, Adamu Nuhu, Abiola Ojumu , Bassey Okposen, Faisal Shuaib, Abdullahi Suleiman, and Salome S. Tor TUNISIA Meha Bergaoui, Nesrine Boujenoui, Abdelkrim Brini, Leila Diffallah, Essia Ben Farhat Hmida, , Ramzi Ouhichi, Nabil Ben Salah, Mme. Sihem, and Mahrez Yahyaoui Funding for this document was provided by Task Force for Global Health through the support of the Bill and Melinda Gates Foundation. TABLE OF CONTENTS Acknowledgements .............................................................................................................2 Executive Summary .............................................................................................................4 Introduction ........................................................................................................................5 The Path to Polio Eradication ......................................................................................................................5 Bringing In Every Possible Tool ...................................................................................................................5 Unprecedented Pace for IPV Introduction ...................................................................................................6 Progress ....................................................................................................................................................6 Albania ..............................................................................................................................7 Introduction ...............................................................................................................................................8 Decision-Making ........................................................................................................................................8 Pre-Introduction Activities ..........................................................................................................................9 Implementation ........................................................................................................................................10 Lessons Learned ......................................................................................................................................10 Timeline ...................................................................................................................................................11 Nigeria .............................................................................................................................12 Introduction .............................................................................................................................................13 Decision-Making ......................................................................................................................................13 Pre-Introduction Activities ........................................................................................................................14 Implementation ........................................................................................................................................16 Lessons Learned ......................................................................................................................................16 Timeline ...................................................................................................................................................17 Tunisia .............................................................................................................................18 Introduction .............................................................................................................................................19 Decision-Making ......................................................................................................................................19 Pre-Introduction Activities ........................................................................................................................20 Implementation ........................................................................................................................................20 Lessons Learned ......................................................................................................................................20 Timeline ...................................................................................................................................................22 International Vaccine Access Center (IVAC) • Johns Hopkins Bloomberg School of Public Health | 3 EXECUTIVE SUMMARY Since its launch at the 44th World Health Assembly in 1988, the Albania, Nigeria, and Tunisia. Each case study describes the Global Polio Eradication Initiative (GPEI) has reduced the global decision-making process, the pre-introduction activities that incidence of polio by more than 99% and the number of countries were conducted, and the implementation process for each with endemic polio from 125 to 3. While this progress is immense, a country. Each case study concludes with a synthesis of the great deal of work is still required for full eradication of the disease. lessons learned during IPV introduction that can be applied to other countries. Using the lessons learned from Albania, Nigeria, There are two vaccines used to prevent polio: (1) the oral Polio and Tunisia—both their successes and their challenges— vaccine (OPV) and (2) the inactivated polio vaccine (IPV). OPV other countries have the opportunity to take advantage of the is extremely safe and effective at protecting children against strategies which were most effective and avoid common pitfalls. lifelong paralysis caused by the poliovirus. Over the past ten years, more than 10 billion doses of OPV have been given to Many of the findings from these case studies are programmatic nearly three billion children worldwide. More than 10 million and therefore applicable to not only IPV but also to the cases of polio have been prevented, and the disease has been introduction of other vaccines. reduced by more than 99%. It is the appropriate vaccine through which to achieve global polio eradication. However, OPV Albania, Nigeria, and Tunisia were selected because they are contains attenuated (weakened) polioviruses. On extremely rare geographically and economically diverse. Nigeria, is located in occasions, the use of OPV can result in paralysis due to vaccine- Africa and is eligible for financial support from Gavi, the Vaccine associated paralytic polio (VAPP) and circulating vaccine-derived Alliance. Albania is located in Europe and is an upper-middle polioviruses (cVDPVs). For this reason, the global eradication income country that was Gavi-eligible until 2013. Finally, Tunisia of polio requires the cessation of all OPV use in routine is located in the Eastern Mediterranean and is an upper-middle immunization (RI), as soon as possible after the eradication income country. Unlike Albania, Tunisia has never been Gavi- of wild poliovirus (WPV) transmission. This will leave only IPV eligible and has always self-financed all vaccine introductions. in widespread use, which eliminates the chance of VAPP cases and the circulation of cVCPVs (IPV does not cause these), By comparing and contrasting this diverse set of countries for allowing for complete eradication of all polioviruses in the world. this case study, it is possible to illustrate some of the similarities and differences between countries related to these factors. At the end of 2012, global immunization experts made a landmark recommendation that every country in the world Reasons for success seen across countries exclusively using the oral polio vaccine (OPV) should add • IPV was best accepted by caregivers in countries where there at least one dose of the inactivated polio vaccine (IPV) to was a history of public trust in the immunization program. their national immunization schedule by the end of 2015. • Strong, clear and simple messages are the most effective The primary role of introducing one dose of IPV into routine for caregivers. In some countries, the most effective immunization programs is to mitigate risks associated with messages did not specifically mention polio, IPV, or OPV. OPV withdrawal and possible reintroduction of polioviruses. The messages simply stated that a new vaccine was being introduced
Load more

Recommended publications
  • Vaccinator Training Plan Workstream 4: Vaccine Process and Workforce Subgroup 3: Workforce Planning and Training
    Vaccinator Training Plan Workstream 4: Vaccine Process and Workforce Subgroup 3: Workforce Planning and Training Health Service Executive Vaccinator Training Plan COVID-19 Vaccination Programme Subgroup 3: Workforce Planning and Prepared by Training [New Vaccinator Working Group] David Walsh, Workstream Lead Approved by Vaccination Process and Workforce Date 15th April2021 Version 02 1 Vaccinator Training Plan Workstream 4: Vaccine Process and Workforce Subgroup 3: Workforce Planning and Training Table of Contents Introduction .................................................................................................................................................... 3 Scope of the Training Programme .................................................................................................................. 3 Training Programme Delivery Approach ........................................................................................................ 6 Develop Training Programmes.................................................................................................................... 6 Deliver Vaccinator Training ......................................................................................................................... 7 Delivering the Training .................................................................................................................................... 9 Introduction ...............................................................................................................................................
    [Show full text]
  • Vaccinator Required Pre-Clinic Training
    Vaccinator required pre-clinic training Training (click title to be directed to training PDF or website) Type of Training Page number POD Vaccination Clinic Overview PDF 2 POD Role Description PDF 18 Complete COVID-19 Vaccine Training: General Overview of Web training Web Immunization Best Practices for Healthcare Providers Moderna - CDC’s COVID-19 Vaccine: What Healthcare Web training Web Professionals Need to Know Moderna’s EUA Factsheet for providers PDF 23 Moderna’s EUA Factsheet for recipients PDF 45 Review of information on Moderna’s website Webpage Web Review of CDC’s information on Moderna vaccine Webpage Web Moderna COVID-19 Vaccine; Vaccine Preparation and Webpage Web Administration Summary Pfizer - CDC’s COVID-19 Vaccine: What Healthcare Professionals Web training Web Need to Know Pfizer’s EUA Factsheet for providers PDF 50 Pfizer’s EUA Factsheet for recipients PDF 80 Pfizer-BioNTech COVID-19 Vaccine; Vaccine Preparation and Webpage Web Administration Summary Review CDC’s information on Pfizer’s vaccine Webpage Web Health Department’s Immunization Protocol PDF 86 Health Department’s Medical Orders for COVID-19 Vaccines PDF 89 Health Department’s Bloodborne Pathogen Plan and Appendices PDF 93 2, 4, 5 & 6 Health Department’s Emergency Care and Adverse Event PDF 111 Guidelines Health Department’s Epinephrine Medical Order PDF 116 VAMS Sheet for Healthcare Providers and video attached to email PDF 118 When I Work Training PDF 119 Agency of Human Services HIPAA Awareness Training PDF 132 Review CDC’s Interim Considerations: Preparing
    [Show full text]
  • Oregon's COVID-19 Vaccination Plan
    COVID-19 Vaccination Plan OREGON Oregon Health Authority | Oregon Immunization Program 11/6/2020 | INTERIM DRAFT 1.1 OREGON COVID-19 VACCINATION PLAN Table of Contents Record of Changes ..................................................................................................... 3 Introduction: Oregon’s COVID-19 Vaccine Plan ..................................................... 4 Health Equity Definition ............................................................................................ 4 Disproportionate Effects of COVID-19 ..................................................................... 5 Roots of Inequity: Social Determinants of Health and Determinants of Equity .... 5 Communities of Color are Disproportionately Affected by COVID-19 ................ 5 Historical Disparities .............................................................................................. 7 A Path Forward .......................................................................................................... 8 Governor’s Health Equity Framework ................................................................... 8 Co-Creation Process ............................................................................................... 9 Section 1: COVID-9 Vaccination Preparedness Planning .......................................11 Section 2: COVID-19 Organizational Structure and Partner Involvement .............15 Coronavirus Response and Recovery Unit (CRRU) ............................................16 Health Security, Preparedness and
    [Show full text]
  • Ensuring Access to COVID-19 Vaccines for Older Adults and People with Disabilities Who Are Homebound
    Ensuring Access to COVID-19 Vaccines for Older Adults and People with Disabilities Who Are Homebound Recommendations and Considerations for Federal, State, and Local Agencies and their Partners Trust for America’s Health — May 2021 2 Contents Executive Summary ....................................................................................................................................... 3 Background ................................................................................................................................................... 4 Barriers to Ensuring Vaccine Access for Those Who Are Homebound ..................................................... 6 Recommendations and Considerations ........................................................................................................ 7 Prioritize the Homebound Population ...................................................................................................... 9 Define the Homebound Population ........................................................................................................ 10 Equitably Vaccinate People Who Are Homebound ................................................................................ 11 Collect and Utilize Data to Ensure Equitable Access ............................................................................... 13 Proactively Register People Who Are Homebound for Vaccination ....................................................... 13 Develop Flexible and Creative Vaccine Allocation Plans .......................................................................
    [Show full text]
  • ACIP-Vaccinate with Confidence for COVID-19 Vaccine-October 30, 2020
    Vaccinate with Confidence for COVID-19 Vaccines Amanda Cohn, MD October 30, 2020 For more information: www.cdc.gov/COVID19 Rising to the challenge to achieve high coverage with COVID-19 vaccines Influenza Vaccination Coverage, ≥18 years, by Race/Ethnicity: 2008-09 – 2017-18 60 . We need novel and 50 more robust strategies 40 Overall to increase demand and 30 White, NH uptake of COVID-19 20 Black, NH vaccines, once available Percent Vaccinated Percent Hispanic 10 Other* 0 Source: Vaccination Coverage among Adults in the United States, National Health Interview Survey, CDC, 2017. NH = Non-Hispanic. Vaccinations included in this assessment include influenza, pneumococcal, Td, Tdap, Zoster, HepA, HepB, and HPV. 10/27/20 The vaccine demand continuum INCREASING CONFIDENCE IN VACCINE, VACCINATOR, AND HEALTH SYSTEM Vaccination hesitancy: Accept some, delay some, refuse some Demand Refuse Passive all vaccines Acceptance Adapted from source:Source: SAGE GVAP Working Strategic Group onObjective Vaccine Hesitancy 2 Working 2017 Group A new pandemic, a new vaccine, and a new adult- focused platform means shifting tactics . Individuals across the continuum will have concerns. These concerns are understandable and need to be addressed with empathy and transparency. Concerns among healthcare providers is a risk for overall vaccine confidence. Healthcare providers are the most trusted source for health information. Communities will have unique experiences informing COVID-19 vaccine perceptions. Engagement with community organizations and leaders will expand access to clear and accurate information on COVID-19 vaccines. DRAFT A National Strategy to Reinforce Confidence in COVID-19 Vaccines Reinforce Objective: Regularly share clear and accurate COVID-19 vaccine information and take Trust visible actions to build trust in the vaccine, the vaccinator, and the system.
    [Show full text]
  • PREP Act Fact Sheet: Expanding the COVID-19 Vaccination Workforce
    Expanding the COVID-19 Vaccination Workforce COMMITMENT TO ENDING THE COVID- 19 PANDEMIC The federal government is committed to providing enough COVID-19 vaccine for every adult in America who wants to be vaccinated. The Biden Administration is supporting state, local, territorial, and tribal (SLTT) health agencies in administering the vaccines equitably as they become increasingly available. As of March 2021, the U.S. Food and Drug Administration (FDA) has authorized three safe and effective vaccines for emergency use, and federal agencies continue to work with other companies on clinical trials of additional vaccines. Additionally, the federal government has taken significant steps to expand the manufacturing capacity of the authorized vaccines and the supplies needed to administer them. THE NEED FOR VACCINATORS As hundreds of millions more vaccine doses are manufactured and distributed throughout the country, more locations and more healthcare personnel qualified to administer those vaccine doses may be needed. Through the Public Readiness and Emergency Preparedness (PREP) Act Declaration, the federal government has provided a pathway for SLTTs to rapidly expand and support their vaccination workforces as needed – including some healthcare professionals and students in healthcare professions not traditionally in the role of vaccinator and retired healthcare professionals. The PREP Act Declaration should be used by SLTTs to complement other efforts to enhance vaccination awareness and administration, such as health education. In addition, states are encouraged to further expand the categories of persons authorized to administer COVID-19 vaccines in their states, as authorized under the PREP Act, to respond to local needs and availability of potential vaccinators.
    [Show full text]
  • Community-Based COVID-19 Vaccination Manual Lessons and Insights from Frontline Operations
    Community-based COVID-19 Vaccination Manual Lessons and insights from frontline operations Photo courtesy of CORE March 2021 Community-based COVID-19 Vaccination Manual Lessons and insights from frontline operations www.coreresponse.org www.pih.org Acknowledgements CORE would like to thank all of our vaccination partners for their tremendous support and collaboration. In Los Angeles: City of Los Angeles, Los Angeles Fire Department, Los Angeles County Department of Public Health, Carbon Health, USC School of Pharmacy, Curative, World Central Kitchen, All Hands and Hearts, Herald Christian Health Center, and our many other critical community partners. Special thanks to the City of LA and the Mayor’s Office for their vision, leadership, and guidance throughout the city’s response to COVID-19. The rapid launch and expansion of testing and vaccination sites across LA, particularly in communities hardest hit by the pandemic, would not have been possible without their dedication and willingness to jump in quickly and fully. To our LAFD brothers and sisters in arms - thank you for setting a model for partnership in emergency response. In Georgia: Atlanta-Fulton County Emergency Management Agency, Fulton County Board of Health, Cobb & Douglas Public Health, and International Rescue Committee. Special thanks to the Georgia Department of Public Health and our county partners for their highly collaborative partnerships and continued commitment to health equity. We would also like to thank our dedicated staff and volunteers across the country who have worked tirelessly on the frontlines serving their communities. Finally, we would like to express our gratitude to our fellow citizens, who have made many sacrifices large and small throughout the pandemic and have done their part to protect each other by masking, social distancing, getting tested, and getting vaccinated.
    [Show full text]
  • Meeting the Challenge of Vaccination Hesitancy
    Foreword by Harvey V. Fineberg and Shirley M. Tilghman This publication is based on work funded in part by the Bill & Melinda Gates Foundation. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. The Aspen Institute 2300 N Street, N.W. Suite 700 Washington, DC 20037 Sabin Vaccine Institute 2175 K Street, N.W. Suite 400 Washington, DC 20037 ABOUT THE SABIN-ASPEN VACCINE SCIENCE & POLICY GROUP The Sabin-Aspen Vaccine Science & Policy Group brings together senior leaders across many disciplines to examine some of the most challenging vaccine-related issues and drive impactful change. Members are influential, creative, out-of-the-box thinkers who vigorously probe a single topic each year and develop actionable recommendations to advance innovative ideas for the development, distribution, and use of vaccines, as well as evidence- based and cost-effective approaches to immunization. 1 May 2020 We are pleased to introduce the second annual report of the Sabin-Aspen Vaccine Science & Policy Group: Meeting the Challenge of Vaccination Hesitancy. The package of “big ideas” presented here, and the rigorous evidence and consensus-driven insights on which they rest, reassure us that smart strategies are available not only to maintain, restore, and strengthen confidence in the value of vaccines, but also to underscore the broad societal obligation to promote their use. Implementing those strategies requires concerted commitment, and we are deeply grateful to the members of the Vaccine Science & Policy Group, who have helped us identify pathways to progress.
    [Show full text]
  • North Dakota Covid-19 Vaccination Plan
    INTERIM DRAFT NORTH DAKOTA COVID-19 VACCINATION PLAN Updated December 11, 2020 Version 2.0 1 Significant changes from previous version: • Information regarding ancillary supplies provided by federal government • Additional tabletop exercises and other exercises • Updated information regarding the data use agreement with CDC • Tribal sovereignty to determine priority groups • Redistribution guidance • Vaccine finder inventory reporting • Revised phases for vaccination based on ACIP meetings • Long term care federal pharmacy partnership program • Updated tribal preferences for federal or state allocations • Federal pharmacies for Phase 2 • Updated ultra-cold freezer capacity • Revised assumptions for vaccines A and B • Federal government hold of second doses 2 Contents Significant changes from previous version: ......................................................................................... 2 Acronyms ......................................................................................................................................................... 7 Introduction .................................................................................................................................................... 8 Lessons Learned from H1N1 ................................................................................................................ 9 Response Goals for Pandemic Vaccination ................................................................................... 11 COVID-19 Vaccination Planning Assumptions ...........................................................................
    [Show full text]
  • Catalogue of Interventions Addressing Vaccine Hesitancy
    TECHNICAL REPORT Catalogue of interventions addressing vaccine hesitancy www.ecdc.europa.eu ECDC TECHNICAL REPORT Catalogue of interventions addressing vaccine hesitancy This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), under the Framework Service Contract ECDC/2014/013 with World Health Communication Associates (WHCA) and sub- contracted to the London School of Hygiene and Tropical Medicine (LSHTM). It was coordinated by Andrea Würz, with contributions from Irina Ljungqvist and Lucia Pastore Celentano. It was produced by Heidi Larson, Emilie Karafillakis and Clarissa Simas at the London School of Hygiene and Tropical Medicine (LSHTM) – The Vaccine Confidence Project. The following experts were consulted for additional input on interventions addressing vaccine hesitancy: Adriana Baban (Babes-Bolyai University, Romania), Agoritsa Baka (Hellenic Centre for Disease Control and Prevention, Greece), Liesbeth Mollema (National Institute for Public Health and the Environment (RIVM), The Netherlands), Pierluigi Lopalco (University of Pisa, Italy), Pierre Van Damme (University of Antwerp, Belgium), Pierre Verger (National Institute of Health and Medical Research (INSERM), France), Xavier Bosch (Catalan Institute of Oncology (ICO), Spain). Suggested citation: European Centre for Disease Prevention and Control. Catalogue of interventions addressing vaccine hesitancy. Stockholm: ECDC; 2017. Stockholm, April 2017 PDF ISBN 978-92-9498-055-7 doi: 10.2900/654210 Catalogue number TQ-01-17-377-EN-N © European
    [Show full text]
  • Interpersonal Communication for Immunization Training for Front Line Workers
    Facilitator guide Interpersonal Communication for Immunization Training for Front Line Workers UNICEF Europe and Central Asia Region Facilitator guide Interpersonal Communication for Immunization Training for Front Line Workers UNICEF Europe and Central Asia Region 4 Interpersonal Communication for Immunization. Facilitator guide Acknowledgements This training package was developed by the Johns Hopkins Center for Communication Programs, the UNICEF Europe and Central Asia Regional Office, and UNICEF Country Office staff in Bosnia and Herzegovina and Serbia. We would like to thank Sergiu Tomsa, UNICEF Regional Communication for Development Specialist, Mario Mosquera, UNICEF Regional Communication for Development Adviser and Svetlana Stefanet, UNICEF Regional Immunization Specialist, for their significant contributions to its conceptualization and development. We also thank Fatima Cengic, Health and Nutrition Specialist, UNICEF Bosnia and Herzegovina and Jelena Zajeganovic-Jakovljevic, Early Childhood Development Specialist, UNICEF Serbia, as well as Dragoslav Popovic, consultant, the representatives of Institutes of Public Health, academia, health workers, Roma community mediators and civil society organizations from both countries for their support and active engagement in pre-testing and finalizing the package. The materials are based on state-of-the-art resources from UNICEF, the World Health Organization (WHO), European and American Centers for Disease Control, academic journals and the immunization websites of a range of governments
    [Show full text]
  • Federal Healthcare Resilience Work Group EMS/Prehospital Team
    Federal Healthcare Resilience Work Group EMS/Prehospital Team Utilization of Emergency Medical Services (EMS) Clinicians as Vaccinators for COVID-19 Vaccine Administration Product (EMS54) Purpose This document is designed to serve as an information resource for EMS agencies assisting state or local health departments, or other agencies, with COVID-19 vaccination programs. This document applies to all EMS delivery models including but not limited to; free standing, municipal third-service, fire-based, hospital-based, private, independent, law enforcement, volunteer, military, federal, and related EMS clinicians. Developed By The Federal Healthcare Resilience Working Group (HRWG), formerly the Healthcare Resilience Task Force (HRTF), is leading the development of a comprehensive strategy for the U.S. healthcare system to facilitate resiliency and responsiveness to the threats posed by COVID-19. The Working Group’s EMS/Pre-Hospital Team is comprised of public and private-sector emergency response and 911 experts from a wide variety of agencies and focuses on responding to the needs of the pre-hospital community. This Team is composed of subject matter experts from the National Highway Traffic Safety Administration (NHTSA) Office of Emergency Medical Services (OEMS), National 911 Program, Centers for Disease Control and Prevention (CDC), Federal Emergency Management Agency (FEMA), U.S. Fire Administration (USFA), U.S. Army, U.S. Coast Guard (USCG), and consults with non-federal partners representing stakeholder groups and areas of expertise. Through collaboration with experts in related fields, the team develops practical resources for field clinicians/responders, supervisors, administrators, emergency management personnel, medical directors, and associations to better respond to the COVID-19 pandemic.
    [Show full text]